96 /100
CRITICAL RISK
Score updated May 16, 2026

ARTL — Artelo Biosciences, Inc. Dilution Risk Tracker

Track ARTL dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ARTL — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
100
💰 Cash Runway
95
📊 Float Risk
80
⚠️ Warrant Exposure
90
🔄Convertible Debt

🌦️ Dilution Forecast

🌩️
Severe
Multiple high-probability dilution events detected
67%
💰 Capital Raise 93%
• Critical: only 1.7 months cash remaining
• Active shelf registration ($75M, 1868% of market cap)
📜 Warrant Exercise 60%
• Massive warrant overhang: 464% of shares outstanding
• Warrant risk score very high (90/100)
🔄 Reverse Split 15%
• Only 2 months cash — financial pressure
🔔 Track ARTL — Get forecast alerts →

💹 Market Data

Market Cap$4.02M
Shares Outstanding2.18M
Float644.7K
Cash$600.0K
Debt$678.0K
Short InterestN/A

🏛 Institutional Holdings

8 institutional holders · 32.8K shares
#1 UBS Group AG 11.2K shares
#2 Two Sigma Investments, LP 6.9K shares
#3 Virtu Financial LLC 5.6K shares
+ 5 more holders Sign up free to view →

📉 Short Interest

Short Interest62.5K
Days to Cover1.0
% of Float9.7%
FINRA data as of Apr 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Mar 31, 2026
xbrl XBRL WARRANT Mar 31, 2026
S-3 SHELF May 04, 2026
424B3 ATM Apr 16, 2026
EFFECT EFFECT Apr 15, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track ARTL Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ARTL — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for ARTL
📊 ARTL FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 ARTL Signal Convergence & Dark Pool Activity — StonkWhisper 📄 ARTL Dilution Risk Analysis — Full In-Depth Report

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.